First optical observation of 10B-neutron capture reactions using a boron-added liquid scintillator for quality assurance in boron neutron capture therapy

2021 ◽  
Author(s):  
Akihiro Nohtomi ◽  
Hideya Maeda ◽  
Naoya Sakamoto ◽  
Genichiro Wakabayashi ◽  
Takushi Takata ◽  
...  
Keyword(s):  
Quality Assurance ◽  
Boron Neutron Capture Therapy ◽  
Neutron Capture ◽  
Liquid Scintillator ◽  
Optical Observation ◽  
Neutron Capture Therapy ◽  
Boron Neutron Capture

Quality assurance of patient dosimetry in boron neutron capture therapy

2004 ◽  
Vol 43 (4) ◽  
pp. 404-411 ◽  
Author(s):  
Per M. Munck af Rosenschöld ◽  
Jacek Capala ◽  
Crister P. Ceberg ◽  
Valerio Giusti ◽  
Leif G. Salford ◽  
...  
Keyword(s):  
Quality Assurance ◽  
Boron Neutron Capture Therapy ◽  
Neutron Capture ◽  
Neutron Capture Therapy ◽  
Boron Neutron Capture

Evaluation of silicon based microdosimetry for Boron Neutron Capture Therapy Quality Assurance

2019 ◽  
Vol 66 ◽  
pp. 8-14 ◽  
Author(s):  
James Vohradsky ◽  
Susanna Guatelli ◽  
Jeremy A. Davis ◽  
Linh T. Tran ◽  
Anatoly B. Rosenfeld
Keyword(s):  
Quality Assurance ◽  
Boron Neutron Capture Therapy ◽  
Neutron Capture ◽  
Neutron Capture Therapy ◽  
Boron Neutron Capture ◽  
Silicon Based ◽  
Therapy Quality

scholarly journals HGG-05. REGRESSION OF RECURRENT GLIOBLASTOMA AFTER BORON NEUTRON CAPTURE THERAPY AND CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY IN A CHILD

2020 ◽  
Vol 22 (Supplement_3) ◽  
pp. iii345-iii345
Author(s):  
Hsin-Hung Chen ◽  
Yi-Wei Chen
Keyword(s):  
T Cells ◽  
T Cell ◽  
Chimeric Antigen Receptor ◽  
Boron Neutron Capture Therapy ◽  
Neutron Capture ◽  
Antigen Receptor ◽  
Neutron Capture Therapy ◽  
T Cell Therapy ◽  
Boron Neutron Capture ◽  
Car T

Abstract A 6 y/o girl with recurrent multifocal glioblastoma received 3 times of boron neutron capture therapy (BNCT) and chimeric antigen receptor (CAR)–engineered T cells targeting the tumor-associated antigen HER2. Multiple infusions of CAR T cells were administered over 30 days through intraventricular delivery routes. It was not associated with any toxic effects of grade 3 or higher. After BNCT and CAR T-cell treatment, regression of all existing intracranial lesions were observed, along with corresponding increases in levels of cytokines and immune cells in the cerebrospinal fluid, but new lesions recurred soon after the treatment. This clinical response continued for 14 months after the initiation of first recurrence.

Sign in / Sign up

Export Citation Format

Share Document